ArticleJournal of Parkinson's disease2022
Prevalence of Prodromal Symptoms of Parkinson's Disease in the Late Middle-Aged Population.
Article in Journal of Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 54 citations in OpenAlex.
- Smartphone-Based Multimodal Digital Biomarker Integration for Parkinson's Disease Screening and Diagnostic Support.Neurology and therapy · 2026Article
- Cross-species characterisation of microglial morphology and proliferation during ageing.GeroScience · 2026Article
- Vascular Disease, Non-Steroidal Anti-Inflammatory Drugs and Risk of Parkinson's Disease.Annals of clinical and translational neurology · 2026Article
- The relationship between physical activity levels and measures of cognition and disease severity in prodromal Parkinson's disease: A longitudinal study.BMC neurology · 2026Observational
- Fluorescence Detection of Alpha-Synuclein Aggregates in the Gut Using a Peptide Probe.ACS chemical neuroscience · 2026Article
- Re-conceptualizing Parkinson's disease as a lifelong neurobiological trajectory: A framework for prevention.Neuroprotection (Chichester, England) · 2026Review
- Meaning in life and Parkinson's disease: Evidence from a 17-year study across 14 countries.Archives of gerontology and geriatrics · 2026Article
- The Use of a Digital Social Forum in a Parkinson's Disease Risk Cohort: A Thematic Analysis of Forum Messages.Parkinson's disease · 2026Article
- Machine learning analysis of population-wide plasma proteins identifies hormonal biomarkers of Parkinson's disease.Frontiers in aging neuroscience · 2026Article
- Features of Prodromal Parkinson Disease and Dopaminergic Neurotransmission in Community-Dwelling Older Adults.Neurology · 2025Observational
- Long-term exposure to multiple air pollutants and risk of Parkinson's disease: a population-based multipollutant model study.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Dementia with Lewy bodies and Parkinson disease dementia - the same or different and is it important?Nature reviews. Neurology · 2025Review
- Imaging advances to detect non-motor prodromal markers of Parkinson's disease and explore therapeutic translation opportunities.NPJ Parkinson's disease · 2025Review
- Evidence of COMT dysfunction in the olfactory bulb in Parkinson's disease.Acta neuropathologica · 2025Article
- Obesity and the development of Parkinson's disease within the Framingham Heart study cohort.Clinical parkinsonism & related disorders · 2025Article
- Tracking prodromal Parkinson's disease: a five-year follow-up of the PARCAS cohort.Frontiers in neurology · 2025Article
- Ginsenoside Rg1 in Parkinson's disease: from basic research to clinical applications.Frontiers in pharmacology · 2025Review
- SARS-CoV-2 Infection and Alpha-Synucleinopathies: Potential Links and Underlying Mechanisms.International journal of molecular sciences · 2024Review
- A-Syn(ful) MAM: A Fresh Perspective on a Converging Domain in Parkinson's Disease.International journal of molecular sciences · 2024Review
- Immunological shifts during early-stage Parkinson's disease identified with DNA methylation data on longitudinally collected blood samples.NPJ Parkinson's disease · 2024Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThe prodromal phase of Parkinson's disease (PD) can last up to 20 years and is characterized by a variety of non-motor symptoms.
objectiveTo determine the prevalence of a selection of non-motor symptoms known to be associated with an increased risk of developing PD in a late middle-aged population-based sample and to determine their association with motor function.
methodsAt a mean age of 60.3 years, 775 subjects were recruited from the Longitudinal Aging Study Amsterdam (LASA). Hyposmia, cognitive impairment, patient-reported constipation, possible REM-sleep behavior disorder, depression, and anxiety were indexed as known PD risk factors. Additionally, 1) the PD screening questionnaire, 2) four physical performance tests, and 3) a functional limitations questionnaire, were used to determine whether the presence of two or more PD risk factors was associated with reduced motor function.
resultsThe prevalence of single risk factors ranged between 3 and 13%. Approximately 11% of subjects had two or more PD risk factors. Motor functioning of subjects with two or more PD risk factors was significantly worse than performance of subjects without or with a single risk factor (all p values≤0.001).
conclusionApproximately 11% of the late middle-aged population has two or more known PD risk factors. Among these subjects self-perceived PD symptoms and reduced physical performance are more prevalent, suggesting that at least some of these subjects may be in the prodromal phase of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.